Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPT2D: Effect of Neprilysin Inhibition on GLP-1 in Type 2 Diabetes
NCT03893526Phase 4Completed
- Sponsor
- University of Copenhagen
- Start
- Jan 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of sacubitril in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by University of Copenhagen. Primary endpoint: Blood Glucose at 3 hours. Started Jan 2019; status: completed.
02
Drugs
sacubitril
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03893526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03893526.